ライフサイエンスコーパス: chemotherapeutic agent

1 rosoguanidine (MNNG, a common DNA-alkylating chemotherapeutic agent).

2 timuli (for example, nutrient starvation and chemotherapeutic agents).

3 al acne creams as well as being a first-line chemotherapeutic agent.

4 taxel, an important yet poorly water-soluble chemotherapeutic agent.

5 tion with temozolomide, the standard-of-care chemotherapeutic agent.

6 onal population to cisplatin, a DNA-damaging chemotherapeutic agent.

7 +) tumor targets even in the presence of the chemotherapeutic agent.

8 d CD52, a protein targeted by alemtuzumab, a chemotherapeutic agent.

9 rscoring the compound's potential as a novel chemotherapeutic agent.

10 Cs to cisplatin, a prototypic platinum-based chemotherapeutic agent.

11 e before and 48 hours after treatment with a chemotherapeutic agent.

12 vely resensitized the p53-null cells to this chemotherapeutic agent.

13 f resistance to gemcitabine, a commonly used chemotherapeutic agent.

14 lability limits its further development as a chemotherapeutic agent.

15 to reduce pain in patients treated with this chemotherapeutic agent.

16 t Jurkat cells during apoptotic responses to chemotherapeutic agents.

17 ic target, thus eliminating the need for any chemotherapeutic agents.

18 attractive target for new parasite-specific chemotherapeutic agents.

19 s and pathomechanisms of specific neurotoxic chemotherapeutic agents.

20 e as a defensive shield against conventional chemotherapeutic agents.

21 ry and academia towards the discovery of new chemotherapeutic agents.

22 ar, kidney disease can arise from the use of chemotherapeutic agents.

23 ion with other tyrosine kinase inhibitors or chemotherapeutic agents.

24 that together cause inefficient delivery of chemotherapeutic agents.

25 dose-limiting side effect of many important chemotherapeutic agents.

26 DNA breaks caused by ionizing radiation and chemotherapeutic agents.

27 ir sequential administration after available chemotherapeutic agents.

28 tic alterations or to screen the efficacy of chemotherapeutic agents.

29 nsitization of HCC cells toward conventional chemotherapeutic agents.

30 iology of cancer cells and their response to chemotherapeutic agents.

31 chanism to stress, including that induced by chemotherapeutic agents.

32 re frequently insensitive to traditional AML chemotherapeutic agents.

33 ing the brain against the effects of various chemotherapeutic agents.

34 Cs accounts for positive immunomodulation by chemotherapeutic agents.

35 y and can ultimately improve the efficacy of chemotherapeutic agents.

36 rs cytoprotection against stress stimuli and chemotherapeutic agents.

37 tumor growth, and enhance susceptibility to chemotherapeutic agents.

38 n of apical ballooning syndrome with various chemotherapeutic agents.

39 -specific delivery of appropriately designed chemotherapeutic agents.

40 r, is largely resistant to many conventional chemotherapeutic agents.

41 major pathway of apoptosis induction by many chemotherapeutic agents.

42 veruse and misuse of clinical and veterinary chemotherapeutic agents.

43 g resistance based on the cellular efflux of chemotherapeutic agents.

44 nd protects against cell stressors including chemotherapeutic agents.

45 ng the potential toxicity of other cytotoxic chemotherapeutic agents.

46 drugs, including peptides, antibiotics, and chemotherapeutic agents.

47 rwise sublethal doses of clinically relevant chemotherapeutic agents.

48 and are highly tumorigenic and resistant to chemotherapeutic agents.

49 p mediate resistance of pancreatic tumors to chemotherapeutic agents.

50 ous metabolites and some commonly prescribed chemotherapeutic agents.

51 to glucocorticoid agonists, but not to other chemotherapeutic agents.

52 It also informs the choice of chemotherapeutic agents.

53 wal by serial passages of hepatospheres with chemotherapeutic agents.

54 urvival pathways and conferred resistance to chemotherapeutic agents.

55 iple myeloma cells from apoptosis induced by chemotherapeutic agents.

56 lls, thus improving the therapeutic index of chemotherapeutic agents.

57 nd are the targets of several antibiotic and chemotherapeutic agents.

58 rogression, YAP, AXL, and SRC signaling, and chemotherapeutic agents.

59 owth and sensitizes p53-compromised cells to chemotherapeutic agents.

60 nsitize cancer cells to ferroptosis-inducing chemotherapeutic agents.

61 atinum(II) compounds are a critical class of chemotherapeutic agents.

62 ncreasingly prevalent drug class utilized as chemotherapeutic agents.

63 cological synergisms between FPPa-OmoMYC and chemotherapeutic agents.

64 e survival also of cancer cells treated with chemotherapeutic agents.

65 cells were on the average more resistant to chemotherapeutic agents.

66 r exposure to the common inciting trigger of chemotherapeutic agents.

67 gene confer hypersensitivity to DNA-damaging chemotherapeutic agents.

68 isplatin) are among the most frequently used chemotherapeutic agents.

69 design of COX-2-targeted imaging and cancer chemotherapeutic agents.

70 by death receptors or intrinsic apoptosis by chemotherapeutic agents.

71 Moreover, treatment with the chemotherapeutic agent 5-fluorouracil (5-FU) also induce

72 Blocking cell proliferation via a chemotherapeutic agent 5-fluorouracil (5-Fu) eliminated

73 gher resistance to serial treatment with the chemotherapeutic agent 5-fluorouracil (5-FU).

74 ion, and resistance to the colorectal cancer chemotherapeutic agent 5-fluorouracil.

75 duces the sensitivity of cancer cells to the chemotherapeutic agent 5-fluorouracil.

76 astuzumab and pertuzumab became resistant to chemotherapeutic agents (5-fluoruracil, carboplatin, cis

77 Thus, ATF3 in the host cells links a chemotherapeutic agent-a stressor-to immune modulation a

78 osphorylation of its subunit p65/RelA by the chemotherapeutic agent adriamycin (ADR), but not NF-kapp

79 al foundation to establish it as a promising chemotherapeutic agent against cancer.

80 the promising potential of this complex as a chemotherapeutic agent against cancer.

81 coming drug formulation to be evaluated as a chemotherapeutic agent against malignant melanoma.

82 d its analogs are among the most widely used chemotherapeutic agents against various types of cancer.

83 When compared with the chemotherapeutic agent alone, knockdown of the correspon

84 val of B-ALL cells treated with conventional chemotherapeutic agents alone or in combination with Not

85 opoisomerase inhibitors are in common use as chemotherapeutic agents although they can display reduce

86 ng the use of olaparib in combination with a chemotherapeutic agent and provides a foundation for fut

87 Cladribine was the most commonly used chemotherapeutic agent and was administered in 21 of 63

88 the past four decades because of advances in chemotherapeutic agents and administration protocols as

89 mary and established cancer cells to current chemotherapeutic agents and an anti-VEGF antibody in mTi

90 combinations of conventional small molecule chemotherapeutic agents and biologics.

91 s BAK activation in tumor cells treated with chemotherapeutic agents and is associated with increased

92 s an ABC exporter that extrudes a variety of chemotherapeutic agents and native substrates.

93 To overcome such barriers, a number of chemotherapeutic agents and nucleic acid-based therapies

94 nd increased sensitivity to select cytotoxic chemotherapeutic agents and PARP or ATR inhibitors.

95 are caused by environmental, endogenous, and chemotherapeutic agents and pose a severe threat to geno

96 ) confers resistance to standard-of-care MCC chemotherapeutic agents and provide proof-of-principle t

97 ted a possible association between different chemotherapeutic agents and PVOD.

98 We evaluated the relationship between chemotherapeutic agents and PVOD.

99 exhibited distinct sensitivities toward drug chemotherapeutic agents and radiation as compared with t

100 ells display enhanced resistance to standard chemotherapeutic agents and repopulate tumours after the

101 CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk.

102 our cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, includin

103 from the tumors and tested their response to chemotherapeutic agents and the epithelial growth factor

104 rapy dose and exposed cardiac volume, select chemotherapeutic agents, and age at exposure on risk for

105 erentiation, reversed resistance to multiple chemotherapeutic agents, and impaired tumor growth in vi

106 hibited reduced proliferation, resistance to chemotherapeutic agents, and stem-like metabolic changes

107 avoid potential interactions between ART and chemotherapeutic agents, and the need for HIV-specific s

108 chemoresistance in the AML cells exposed to chemotherapeutic agents, and this was reversed following

109 Paclitaxel (PTX) is one of the most useful chemotherapeutic agents approved for several cancers, in

110 tion of the Notch inhibitor GSI-XII with the chemotherapeutic agent Ara-C lowered bone marrow leukemi

111 rodegenerative changes and a number of newer chemotherapeutic agents are being tested to ameliorate t

112 ny of the current and newly developed cancer chemotherapeutic agents are nephrotoxic and can promote

113 Asparaginase, a widely used chemotherapeutic agent, arrests GAS growth in human bloo

114 esorbable IP microdevice was used to release chemotherapeutic agent at a constant rate of approximate

115 efficacy of an acute myeloid leukemia (AML) chemotherapeutic agent based on a CD33 antibody.

116 Cisplatin is a particularly potent chemotherapeutic agent, but its use to treat GBM is limi

117 ter membrane that would prevent the entry of chemotherapeutic agents, but this could not be tested be

118 gold salt auranofin and the investigational chemotherapeutic agent buthionione sulfoximine (BSO).

119 Notably, cotreatment of chemotherapeutic agent camptothecin enhanced LSD1 inhibi

120 hich is highly expressed in tumours, and the chemotherapeutic agent camptothecin) that self-assemble

121 However, as chemotherapeutic agents can affect the central and perip

122 ironmental exposure, and treatment with some chemotherapeutic agents can all give rise to DNA alkylat

123 , which reduces efficacy, and small-molecule chemotherapeutic agents can be absorbed through the urot

124 he anthracycline doxorubicin (Dox) and other chemotherapeutic agents causes irreversible cardiac dama

125 Chemotherapeutic agents (ChAs) are considered an integra

126 ass of DNA adducts formed by the widely used chemotherapeutic agent cis-diamminedichloroplatinum (cis

127 The chemotherapeutic agent cisplatin is renowned for its oto

128 air the interstrand crosslinks caused by the chemotherapeutic agent cisplatin.

129 ficacious and well-established anthracycline chemotherapeutic agent commonly used in the treatment of

130 in patients receiving immunotherapeutic and chemotherapeutic agents creates a pressing clinical need

131 Our results reveal a mechanism through which chemotherapeutic agents damage rapidly proliferating epi

132 Several chemotherapeutic agents delivered using nanocarriers suc

133 evented peripheral neuropathy induced by the chemotherapeutic agents dichloroacetate and paclitaxel o

134 ion, and the potential for developing cancer chemotherapeutic agents discussed in each case.

135 f chemotherapy when it was combined with the chemotherapeutic agent Doxil, resulting in some longer-t

136 .05) and exhibited decreased response to the chemotherapeutic agent doxorubicin (DOX) (P < 0.01).

137 id not have an impact on permeability of the chemotherapeutic agent doxorubicin (DOX) in a xenograft

138 nd on the sensitivity of cancer cells to the chemotherapeutic agent doxorubicin (DXR) and growth fact

139 Furthermore, antitumor activity of a chemotherapeutic agent (doxorubicin) and immune checkpoi

140 drugs, possibly allowing a reduction of the chemotherapeutic agent effective dose.

141 Doxorubicin (DOX) is a chemotherapeutic agent effective in the treatment of man

142 t the difference in mechanisms of actions of chemotherapeutic agents elicit distinct effects on the c

143 BNPs loaded with a potent chemotherapeutic agent [epothilone B (EB)] showed signif

144 n be stabilized by TOP2 poisons, such as the chemotherapeutic agent etoposide (ETO).

145 2)-DNA adducts induced by treatment with the chemotherapeutic agent etoposide.

146 e glucocorticoid dexamethasone (DEX) and the chemotherapeutic agent etoposide.

147 ABT-869 and chemotherapeutic agents exhibited a strong synergy to in

148 bitor bortezomib, proposed as an alternative chemotherapeutic agent for both primary and cisplatin-re

149 s the potential to be developed further as a chemotherapeutic agent for CRC.

150 h gemcitabine (Gem), a first- or second-line chemotherapeutic agent for PDAC treatment.

151 Paclitaxel is a first line chemotherapeutic agent for the patients with metastatic

152 Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumors

153 cal evaluation of compound 12 as a potential chemotherapeutic agent for TNBC and cancers with constit

154 Malaria control is heavily dependent on chemotherapeutic agents for disease prevention and drug

155 DE cultures were exposed to standard-of-care chemotherapeutics agents for 2 weeks, attesting the abil

156 esistant neoplasms where it effluxes various chemotherapeutic agents from cells.

157 oint kinase inhibitors with the DNA-damaging chemotherapeutic agent gemcitabine offers clinical appea

158 st), as well as pharmacologic assays against chemotherapeutic agents (half-maximal effective concentr

159 hat produces a slow and sustained release of chemotherapeutic agent, has recently been shown to have

160 anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overa

161 Chemotherapeutic agents have certain limitations when it

162 Anti-cancer chemotherapeutic agents have limited access into the bra

163 uccess has been achieved with platinum-based chemotherapeutic agents, i.e. through interactions with

164 ificantly higher sensitivity to the standard chemotherapeutic agents, i.e., doxorubicin (DOX) and cyt

165 Doxorubicin (DOX), a common chemotherapeutic agent, impairs synaptic plasticity.

166 After the approval of cisplatin as a chemotherapeutic agent in 1978, several types of metal-b

167 y, we validate the effectiveness of ALX as a chemotherapeutic agent in vivo by demonstrating its abil

168 eoside analogs DHAs with SIRT6 inhibitors or chemotherapeutic agents in AML due to the role of SIRT6

169 at the mitochondrion ("priming") induced by chemotherapeutic agents in cancer cells, not requiring p

170 xicity of super-therapeutic acetaminophen or chemotherapeutic agents in children, limited data exists

171 ression promotes cellular resistance towards chemotherapeutic agents in cultured CRC cells and colore

172 y (MAb) therapy has been combined with other chemotherapeutic agents in human cancer trials.

173 Lumican secretion was increased by chemotherapeutic agents in PDAC, and especially in PSCs,

174 at sustained exposure of microtubule-binding chemotherapeutic agents in peripheral nerve tissues cann

175 allenges in achieving high concentrations of chemotherapeutic agents in the central nervous system.

176 e research to achieve better optimization of chemotherapeutic agents in the elderly.

177 estigators lowered the dose of radiation and chemotherapeutic agents in the preparative regimen.

178 ave important implications for the choice of chemotherapeutic agents in the treatment of Mdm2-overexp

179 h cisplatin is one of the most commonly used chemotherapeutic agents in the treatment of non-small ce

180 imilarly, PVOD can develop after exposure to chemotherapeutic agents in the treatment of solid and he

181 clinically achievable doses of HRR-inducing chemotherapeutic agents in vitro and in vivo in a murine

182 DGFRs sensitizes mammary epithelial cells to chemotherapeutic agents in vitro and in vivo.

183 n of mutant K-Ras cancer cells to DNA damage chemotherapeutic agents in vitro and in vivo.

184 tly increase the growth inhibitory effect of chemotherapeutic agents in vitro and in vivo.

185 a cell migration, invasion and resistance to chemotherapeutic agents in vitro.

186 However, insensitivity to these chemotherapeutic agents including cisplatin is common.

187 nergistic therapeutic effects with different chemotherapeutic agents including doxorubicin, l-asparag

188 ion of those MDR tumor cells to conventional chemotherapeutic agents, including cisplatin, sorafenib,

189 Several chemotherapeutic agents, including paclitaxel (Taxol), i

190 ently, it is the target of several antitumor chemotherapeutic agents, including the AR antagonist MDV

191 r than 3 g/dL, and receipt of no more than 2 chemotherapeutic agents independently predicted better s

192 Chemotherapeutic agents induce complex tissue responses

193 B-IL-17RB axis protected leukemic cells from chemotherapeutic agent-induced apoptotic effects.

194 otherapy in PDAC cells through inhibition of chemotherapeutic agent-induced autophagy.

195 Identification of novel drug targets and chemotherapeutic agents is a high priority in the fight

196 Resistance to antimicrobial and chemotherapeutic agents is a significant clinical proble

197 r, the efficacy of nanoparticles loaded with chemotherapeutic agents is currently hampered by their f

198 Doxorubicin, a brain-impermeable chemotherapeutic agent, is also readily and selectively

199 Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute an

200 y injury, whether due to ischemic insults or chemotherapeutic agents, is exacerbated by inflammation,

201 various cancers, promote the elimination of chemotherapeutic agents, leading to reduced therapeutic

202 tudy, we found that treating TNBC cells with chemotherapeutic agents led to a significant accumulatio

203 Additionally, the combination of ABT-869 and chemotherapeutic agents led to remarkable suppression of

204 s inhibitors (median RR, 3.39; P < .001) and chemotherapeutic agents (median RR, 1.73; P < .001), wer

205 Isolated limb perfusion (ILP) with the chemotherapeutic agent melphalan is an effective treatme

206 mall intestinal tissue damage induced by the chemotherapeutic agent methotrexate.

207 the PI3K/Akt pathway with certain classes of chemotherapeutic agents might be more complicated than p

208 e results showed that MSNR could deliver the chemotherapeutic agent, MTX to tumor cells and induce ef

209 requency either alone or in combination with chemotherapeutic agents, namely, cisplatin, docetaxel, a

210 However, in spite of effective chemotherapeutic agents, neuropathy and associated defor

211 Docetaxel is a chemotherapeutic agent of the taxane class of drugs for

212 Targeted chemotherapeutic agents often do not result in tumor shr

213 The present study evaluated the effect of chemotherapeutic agents on exosome production and/or rel

214 rgeted anti-cancer compounds and traditional chemotherapeutic agents on the expression of PD-L1 in fo

215 To study the effects of chemotherapeutic agents on the hair follicle, a number o

216 Lastly, we determined the efficacy of chemotherapeutic agents on TMF by impedance spectroscopy

217 ons consistent with increased sensitivity to chemotherapeutic agents or with induction of glioblastom

218 gration and survival of cells in response to chemotherapeutic agents or withdrawal of glucose.

219 carcinoma cells and sensitized cells toward chemotherapeutic agents or X-ray irradiation.

220 h colorectal cancer initially respond to the chemotherapeutic agent oxaliplatin, acquired resistance

221 contemporaneous delivery of the ICD-inducing chemotherapeutic agent, oxaliplatin (OX).

222 The platinum-based chemotherapeutic agent, oxaliplatin, is used to treat ad

223 d heat stimulation) or by treatment with the chemotherapeutic agent paclitaxel (which induces hyperse

224 c human breast cancer cells subjected to the chemotherapeutic agent paclitaxel at the single-cell and

225 nduced by complete Freund's adjuvant and the chemotherapeutic agent paclitaxel in wild-type but not C

226 Here we show that the chemotherapeutic agent paclitaxel triggers CIPN by alter

227 The efficacy of two front-line chemotherapeutic agents (paclitaxel and cisplatin) are d

228 ouse model of toxic neuropathy produced by a chemotherapeutic agent, paclitaxel.

229 ne of the most effective and frequently used chemotherapeutic agents, paclitaxel produces peripheral

230 d disease is acquired resistance to multiple chemotherapeutic agents, particularly glucocorticoids.

231 Vincristine, a widely used chemotherapeutic agent, produces painful peripheral neur

232 indicates that cancer cell stress induced by chemotherapeutic agents promote antitumor immune respons

233 HSP70-targeted therapy (but not chemotherapeutic agents) promoted apoptosis in RMS cells

234 ill summarize the immune effects of selected chemotherapeutic agents, radiotherapy and recent results

235 ological malignancies, and the resistance to chemotherapeutic agents remains a major challenge to suc

236 ncers (MDR) and attendant resensitization to chemotherapeutic agents represent a promising strategy f

237 his unidirectional transfer enhanced by some chemotherapeutic agents required cell-cell contacts and

238 ng the capability to design a Rac1-targeting chemotherapeutic agent(s) for autoimmune disorders.

239 lammatory cell death induced by SMAC-mimetic chemotherapeutic agents (small-molecule activators of th

240 Specifically, the chemotherapeutic agent SN-38 is incorporated into a cent

241 e ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX).

242 Our results indicate (a) chemotherapeutic agents stimulate exosome production or

243 Classical chemotherapeutic agents such as cisplatin, often used in

244 sensitized NB cell lines to the treatment of chemotherapeutic agents such as doxorubicin (Dox) and et

245 human primary lymphocytes, p53 induction by chemotherapeutic agents such as ionizing radiation cause

246 tolerance against unrelated standard-of-care chemotherapeutic agents, such as anthracyclines.

247 intratumoral accumulation of coadministered chemotherapeutic agents, such as Doxil and paclitaxel, t

248 ors, co-delivery of survivin inhibitors with chemotherapeutic agents, synchronous targeting of surviv

249 In early-phase clinical trials, chemotherapeutic agents targeting cancer-associated fibr

250 H and cancer have identical characteristics, chemotherapeutic agents targeting the POH-related fibrob

251 ance of glioblastoma (GBM) to the front-line chemotherapeutic agent temozolomide (TMZ) continues to c

252 erapeutic effect was relatively unique among chemotherapeutic agents tested, suggesting distinctive e

253 ithiothymine can act as a more effective UVA chemotherapeutic agent than the currently used 4-thiothy

254 in EpCAM(+) spheroids are more resistant to chemotherapeutic agents than 2D-cultured cells.

255 Doxorubicin is a widely used chemotherapeutic agent that causes dose-dependent cardio

256 cancer cells more sensitive to paclitaxel, a chemotherapeutic agent that induces ER stress-mediated c

257 Here we focus on oxaliplatin, an immunogenic chemotherapeutic agent that is effective in aggressive p

258 3, and 5 after treatment with gemcitabine, a chemotherapeutic agent that is powerfully myelosuppressi

259 Paclitaxel is a microtubule-stabilizing chemotherapeutic agent that is widely used in cancer tre

260 Cabazitaxel is a second-line taxane chemotherapeutic agent that provides additional survival

261 t to DNA damage from the immune response and chemotherapeutic agents that can significantly disrupt g

262 These findings advocate development of chemotherapeutic agents that cause fewer long-term side

263 In mouse hair follicles, those chemotherapeutic agents that disrupted feather formation

264 human cancer cells the ability to counteract chemotherapeutic agents that elicit cell death by damagi

265 , which would be an improvement over current chemotherapeutic agents that indiscriminately kill proli

266 y to sensitize breast and ovarian cancers to chemotherapeutic agents that induce DNA damage.

267 d to antimicrobial resistance but also to be chemotherapeutic agents that may be allergenic and poten

268 pancreatic cancer remains dismal and potent chemotherapeutic agents that selectively target this can

269 When subject to a spatial gradient of a chemotherapeutic agent, the cells in the middle of the s

270 ular target to increase, in combination with chemotherapeutic agents, the sensitivity of treatment, e

271 Upon further encapsulation with chemotherapeutic agents, the VAs show unequaled cooperat

272 smart prodrug, delivering a highly cytotoxic chemotherapeutic agent to cancer tumors.

273 he potential to be combined with established chemotherapeutic agents to change the paradigm of NMIBC

274 The ability of chemotherapeutic agents to induce apoptosis, predominant

275 ul method for an effective local delivery of chemotherapeutic agents to treatment of cancers.

276 geted carriers provide efficient delivery of chemotherapeutic agents to tumor tissue.

277 the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to exacerbate metastasis in mous

278 vely deliver doxorubicin, a standard-of-care chemotherapeutic agent, to GBM cells.

279 In PDAC cells, chemotherapeutic agents triggered autophagosome formatio

280 -dependent and enhanced with temozolomide, a chemotherapeutic agent used as a present standard of car

281 s have similar sensitivities to cisplatin, a chemotherapeutic agent used in the treatment of MM.

282 have been effective for delivery of various chemotherapeutic agents used to combat cancer.

283 A enzymes metabolize endogenous hormones and chemotherapeutic agents used to treat cancer, thereby po

284 zymes sensitize lung adenocarcinoma cells to chemotherapeutic agents via induction of mitochondrial d

285 n a mouse model of neuropathy induced by the chemotherapeutic agent vincristine.

286 ose-limiting side effect of many widely used chemotherapeutic agents.We demonstrate that the developm

287 Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel

288 chemotherapy, and intraocular injections of chemotherapeutic agents were successfully introduced.

289 Mitomycin and platinum-based chemotherapeutic agents were used in 96 (72.2%) and 37 (

290 ving a morphological record of the impact of chemotherapeutic agents, whereas the rachis (feather axi

291 t a new approach to maximize the efficacy of chemotherapeutic agents while reducing dose-related toxi

292 nal antibody to increase the efficacy of the chemotherapeutic agent, while reducing toxicity.

293 Immunochemotherapy combines a chemotherapeutic agent with an immune-modulating agent a

294 Y-I2-BODIPY can act as an immune-stimulatory chemotherapeutic agent with potential applications in cl

295 rveillance by tuning down autophagy, certain chemotherapeutic agents with immunogenic properties may

296 last decades from primarily alkylator-based chemotherapeutic agents with minimal efficacy to the int

297 necessitated the rapid development of newer chemotherapeutic agents with novel mechanisms of action.

298 rs an attractive route of administration for chemotherapeutic agents, with the advantages of high dru

299 a single agent or in combination with other chemotherapeutic agents, without causing appreciable thr

300 Cisplatin is a common and effective chemotherapeutic agent, yet it often causes permanent he